Alabama Academy of Family Physicians
MAY 15, 2025
During the session, the Alabama Academy of Family Physicians actively represented the interests of its members on a range of healthcare initiatives. These funds could be utilized for various purposes, including direct care, operational expenses, and facility maintenance or upgrades.
My Green Doctor
MAY 3, 2025
Powering Health, Protecting the Planet – Why Renewable Energy Belongs in Every Clinic Healthcare professionals have always been trusted voices on public health. This isn’t just about saving the planet—it’s also about saving money, protecting patients, and strengthening our healthcare systems from the inside out.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
JUNE 24, 2024
The event, titled “New and Improved – AMCP Format for Formulary Submissions v5.0,” aims to educate pharmaceutical manufacturers and other healthcare stakeholders on the latest updates and best practices in dossier development. will delve into the specifics of the new and improved Format v5.0.
FDA Law
NOVEMBER 6, 2022
In its petition filed earlier this month, Pfizer challenges HHS’s interpretation of the AKS as “staggeringly overbroad,” contrary to the congressional intent behind the AKS, and a threat to “almost any activity that facilitates patient access to federally funded healthcare.” Background. Pfizer’s Petition to SCOTUS.
FDA Law
AUGUST 4, 2022
Pfizer manufactures tafamidis, a breakthrough treatment for a rare, progressive heart condition known as transthyretin amyloid cardiomyopathy. Whether the Beneficiary Inducement Statute (BIS) is relevant to interpreting the AKS (essentially, no). Background. The Lesson of this Case.
FDA Law
JUNE 16, 2023
Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers. We address each below. Best price?
FDA Law
OCTOBER 14, 2021
Given these onerous requirements, it is not a surprise that RAS device manufacturers have not sought clearance for RAS devices for oncology procedures. It would also be beyond the scope of what RAS device manufacturers are intending to offer, which is a better surgical tool, not a therapeutic for cancer. 21 U.S.C. §
Expert insights. Personalized for you.
130 
Let's personalize your content